相关实验视频
Updated: Jul 26, 2025

Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
与中等或高风险肺栓塞患者的全身血栓溶解和抗凝治疗相比,导管导向的血栓溶解:系统性审查和网络元分析
David Planer1, Stav Yanko1, Ilan Matok1
1Department of Cardiology, Hadassah Medical Center, Faculty of Medicine (Planer, Amir, Elbaz-Greener, Raccah) Hebrew University of Jerusalem, Israel; Division of Clinical Pharmacy, Institute for Drug Research, School of Pharmacy, Faculty of Medicine (Yanko, Matok, Zmiro, Rotshild, Raccah), Hebrew University of Jerusalem, Israel; Braun School of Public Health and Department of Hematology, Faculty of Medicine (Paltiel), Hebrew University of Jerusalem, Israel.
与单独使用全身血栓溶解或抗凝药相比,导管血栓溶解 (CDT) 可能会降低肺栓塞 (PE) 的死亡风险. 这项分析表明,CDT可能是中期至高风险PE患者的可行的一线治疗方法.
科学领域:
- 心脏病学 心脏病学
- 干预性肺病学 干预性肺病学
- 医疗技术 医疗技术 医学技术
背景情况:
- 中高风险患者的肺栓塞 (PE) 管理包括抗凝药,全身血栓溶解和导管导向血栓溶解 (CDT).
- 在医疗界,CDT的确切作用和比较有效性仍在争论中.
- 这项研究旨在澄清CDT的疗效和安全性,与PE的替代疗法相比.
结论:
- 与系统性血栓溶解相比,CDT具有中等的确定性表明,死亡和主要出血并发症的风险较低.
- 与抗凝药相比,CDT与可能较低的死亡风险和类似的脑内出血风险有关.
- 研究结果表明,CDT可能被认为是被诊断为中等或高风险肺栓塞的患者的主要治疗选择.
相关概念视频
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism III: Nursing Management
Pulmonary Embolism I: Introduction
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

